Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Aspirin is vital for preventing recurrent myocardial infarction and stent thrombosis in Coronary Artery Disease (CAD) patients undergoing Percutaneous Coronary Intervention (PCI).
• Dual antiplatelet therapy, including aspirin, is standard post-PCI, but aspirin hypersensitivity presents a clinical challenge.
• Limited data exists on the safety and efficacy of alternative antiplatelet regimens excluding aspirin.

Purpose of the Study:

• To review the challenges posed by aspirin hypersensitivity in patients undergoing PCI.
• To propose a treatment algorithm for managing these patients effectively.

Main Methods:

• Literature review focusing on aspirin hypersensitivity, CAD management, and PCI.
• Analysis of current treatment guidelines and clinical evidence.
• Development of a clinical decision-making algorithm.

Main Results:

• Genuine aspirin hypersensitivity is infrequent but complicates PCI management due to lack of validated alternatives.
• Aspirin desensitization is a viable option but not always practical.
• Existing evidence on aspirin-free antiplatelet strategies post-PCI is limited.

Conclusions:

• Managing aspirin hypersensitivity in PCI patients requires careful consideration of risks and benefits.
• A structured approach, potentially including desensitization or alternative therapies, is needed.
• Further research is essential to validate aspirin-free antiplatelet regimens in this population.